IFI-U · 5-Ribonucleotide

Specimen SS-F-UMA-896 // UMAMI · IFI-U

5-Ribonucleotide II-IV-B

Lentinus edodes

Shiitake

Tier II5-Ribonucleotide

Target Trait

2.93×

fold-change

5′-ribonucleotide panel (IMP/GMP/AMP) accumulation index

Technical Specifications

SKU

SS-F-UMA-896

Genomic Edits

6

GC Content

47.3-53.3%

Construct Length

3,574 bp

Promoter System

T7/SP6 cell-free

Expression System

Cell-free T7/SP6 in-vitro

Host Strain

Cell-free

Receptor Target

mGluR1 / TAS1R1-TAS1R3

IFI Score

293

Pathway Edits

  • LeADSS adenylosuccinate synthase overexpression under strong gpd promoter for de-novo IMP elevation feeding all three 5′-ribonucleotide branches
  • LeIMPDH2 inosine monophosphate dehydrogenase isoform 2 upregulation for GMP branch augmentation alongside IMP accumulation
  • LeAK1 adenylate kinase 1 overexpression for AMP/ADP/ATP equilibration, maintaining free AMP concentration as third umami 5′-ribonucleotide co-agonist
  • LeAMPD AMP deaminase partial knockdown (45%) to preserve AMP from conversion to IMP, maintaining all three 5′-nucleotide species simultaneously
  • LeRNase T1 upregulation for endogenous RNA hydrolysis releasing purine nucleotides in post-harvest drying phase of shiitake production
  • LePNP purine nucleoside phosphorylase activity optimization for balanced inosine/guanosine/adenosine salvage supporting all three 5′-nucleotide pools

Key Interventions

Broad 5′-ribonucleotide panel engineering (IMP + GMP + AMP) for maximum TAS1R1/TAS1R3 receptor saturation via three-nucleotide co-agonismPost-harvest RNA hydrolysis pathway activation via RNase T1 for natural nucleotide release in dried shiitake as commercial umami ingredientPurine salvage pathway optimization ensuring balanced IMP:GMP:AMP co-accumulation for synergistic mGluR1 receptor activation pattern

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
293
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Premium dried shiitake mushroom powder, high-grade mushroom extracts, and natural umami seasoning applications where the full 5′-ribonucleotide spectrum amplifies perceived umami intensity via three-co-agonist TAS1R1/TAS1R3 saturation.

License

$749 · Tier II License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Umami · IFI-UAll Modalities